Three enabling tools moved closer to commercial adoption in genomics and translational biology. EndoDNA launched BIOS, a clinical decision-support platform that integrates curated variant-level evidence across about 1 million validated variants and pathway systems for pharmacogenomic and clinical reporting use. Toyobo introduced the Catarosev exosome isolation kit built on a precision microfiltration membrane with ion-exchange and size-based separation characteristics aimed at efficient small extracellular vesicle recovery. Revolune expanded availability of its multiplex immunofluorescence reagent portfolio designed for scalable spatial biology workflows. Together, the releases underline continuing efforts to productize genomic interpretation, EV handling and spatial biomarker detection—capabilities that typically determine how quickly discovery findings can translate into clinical studies.